JRCT ID: jRCTs051200021
Registered date:28/05/2020
Phase II study of new risk classification and high-dose chemotherapy for medulloblastoma
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | Medulloblastoma |
Date of first enrollment | 15/06/2020 |
Target sample size | 229 |
Countries of recruitment | |
Study type | Interventional |
Intervention(s) | With the introduction of new risk classification that combines the molecular classification and the conventional risk factor (M stage), three risk groups for ages 4 and older (low risk (LR), standard risk (SR) and high risk (HR)) and two risk groups for age less than 4 years (standard risk (SR) and high risk (HR)) are defined. In all patients, intrathecal chemotherapy with MTX (IT-MTX) is performed concomitantly with chemotherapy. For all risk groups patients less than 4 years old, induction chemotherapy intensified with high-dose MTX and following high-dose chemotherapy with thiotepa and melphalan (HDC-TM) is planned. For all HR patients and SR patients with residual tumor after HDC-TM, 50.4 Gy of local irradiation and maintenance therapy with IT-MTX are added. For all patients aged 4 years or older, induction chemotherapy with IT-MTX and following chemoradiotherapy including craniospinal irradiation (CSI) is planned. The doses of CSI are 18 Gy for LR and SR and 23.4 Gy for HR. Following chemoradiotherapy, HDC-TM is added for SR and HR patients. The dose of local irradiation is 50.4 Gy (54 Gy if residual before irradiation) for all risk groups. |
Outcome(s)
Primary Outcome | Age greater than or equal to 4 years without metastases: 5yr progression-free survival Age greater than or equal to 4 years with metastases: 5yr progression-free survival Age less than 4 years without metastases: 3yr progression-free survival Age less than 4 years with metastases: 3yr progression-free survival |
---|---|
Secondary Outcome | 3yr and 5 yr overall survival Response rate Pattern of relapse Rate of adverse effect (CTCAE grade 3-5) Neurocognitive function (2yr and 5yr) Rate of secondary neoplasms (2yr and 5yr) Rate of endocrine disorders (2yr and 5yr) Rate of cerebrovascular event (2yr and 5yr) Confirmation rate of risk classification based on molecular classification |
Key inclusion & exclusion criteria
Age minimum | >= |
---|---|
Age maximum | < 30age old |
Gender | Both |
Include criteria | 1) Locally diagnosed as medulloblastoma after tumor resection or biopsy 2) Protocol treatment can be started within 6 weeks after surgery 3) Less than 30 years 4) No prior radiation or chemotherapy 5) ECOG Performance Status (PS) is 3 or less |
Exclude criteria | 1) Active double cancer (synchronous double cancer and metachronous double cancer with disease-free period of 5 years or less). 2) Complicated with extracranial metastasis (M4). 3) Complicated heart disease requiring treatment. 4) You are pregnant or nursing. |
Related Information
Primary Sponsor | Hara Junichi |
---|---|
Secondary Sponsor | Japan Agency for Medical Research and Development |
Source(s) of Monetary Support | |
Secondary ID(s) | Nil known |
Contact
Public contact | |
Name | Kai Yamasaki |
Address | 2-13-22, Miyakozimahondori, Miyakozima-ku, Osaka Osaka Japan 534-0021 |
Telephone | +81-6-6929-1221 |
ka-yamasaki@med.osakacity-hp.or.jp | |
Affiliation | Department of Pediatric Hematology and Oncology, Osaka City General Hospital |
Scientific contact | |
Name | Junichi Hara |
Address | 2-13-22, Miyakozimahondori, Miyakozima-ku, Osaka Osaka Japan 534-0021 |
Telephone | +81-6-6929-1221 |
j-hara@med.osakacity-hp.or.jp | |
Affiliation | Department of Pediatric Hematology and Oncology, Osaka City General Hospital |